← All trials
NCT05118672
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2022
- Primary completion
- Dec 30, 2024
- Completion date
- Mar 30, 2025
- First posted
- Nov 12, 2021
- Last posted
- Nov 12, 2021
- Enrollment
- 478
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eurofarma Laboratorios S.A.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.